文献速递泌尿生殖与妇科肿瘤放疗

美国宫颈癌近距离放疗应用趋势更新:一项监测、流行病学与最终结果研究

Updated Trends in the Utilization of Brachytherapy in Cervical Cancer in the United States: A Surveillance, Epidemiology, and End-Results Study.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-11-10

该研究基于SEER数据库分析2000至2020年间8500例接受体外 beam 放疗的IB2-IVA期宫颈癌患者,发现近距离放疗使用率从2003年最低44%改善至2018-2020年的76%;倾向性评分匹配后,近距离放疗与更低的宫颈癌特异性死亡率和全因死亡率独立相关。

要点

  • 8500例中64%接受近距离放疗联合EBRT,36%仅接受EBRT。
  • 近距离放疗使用率2003年最低44%,2018-2020年改善至76%。
  • 匹配队列中近距离放疗组4年癌症死亡累积发生率32.1% vs 43.4%,P<.001。

核心结论

  • 自2004年以来SEER区域IB2-IVA期宫颈癌患者的近距离放疗使用率有所改善。
  • 近距离放疗使用与显著更低的宫颈癌特异性死亡率和全因死亡率独立相关,是局部晚期宫颈癌治疗的重要组成部分。

研究设计与样本

  • 基于SEER数据的回顾性队列研究,纳入2000至2020年间8500例2009 FIGO IB2-IVA期接受EBRT的宫颈癌患者。
  • 采用逻辑回归分析近距离放疗使用相关因素,并使用倾向性评分匹配调整组间差异。
  • 匹配队列中采用多变量Cox回归评估近距离放疗与宫颈癌特异性死亡率及全因死亡率的关联。

主要发现

  • 8500例女性中64%接受近距离放疗联合EBRT,36%仅接受EBRT。
  • 近距离放疗使用率在2003/2004年急剧下降(2003年最低44%),随后逐渐改善,尤其是2018至2020年达到76%。
  • 与近距离放疗使用几率更高相关的因素包括较年轻年龄、已婚(vs 单身)、较晚诊断年份、某些SEER区域和较早分期。
  • 倾向性评分匹配队列中,近距离放疗与更低的4年癌症死亡累积发生率相关(32.1% vs 43.4%;P < .001)。
  • 匹配队列中近距离放疗与更好的总生存相关(64.0% vs 51.4%;P < .001),并与更低的宫颈癌特异性死亡率(HR 0.70;95%CI 0.64-0.76;P < .001)和全因死亡率(HR 0.72;95%CI 0.67-0.78;P < .001)独立相关。

临床怎么用

  • 原文结论指出近距离放疗是局部晚期宫颈癌患者治疗的重要组成部分。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Our previous Surveillance, Epidemiology, and End Results (SEER) study revealed a concerning decline in brachytherapy utilization in the United States between 1988 and 2009. This study evaluates recent trends in brachytherapy utilization in cervical cancer and identifies factors and survival benefit associated with the use of brachytherapy treatment. METHODS AND MATERIALS: Using SEER data, 8500 patients with International Federation of Gynecologists and Obstetricians 2009 stage IB2-IVA cervical cancer treated with external beam radiation therapy (EBRT) between 2000 and 2020 were identified. Logistic regression analysis was performed on potential factors associated with brachytherapy use: age, marital status, race, ethnicity, income, metropolitan status, year of diagnosis, SEER region, histology, grade, and stage. To adjust for differences between patients who received brachytherapy and those who did not, propensity-score matching was used. Multivariable Cox regression analysis assessed the association of brachytherapy use with cervical cancer-specific mortality (CSM) and all-cause mortality (ACM) in the matched cohort. RESULTS: Sixty-four percent of the 8500 women received brachytherapy in combination with EBRT; 36% received EBRT alone. The brachytherapy utilization rate declined sharply in 2003/2004 (lowest rate 44% in 2003) and then gradually improved especially in 2018 to 2020 (76%). Factors associated with higher odds of brachytherapy use included younger age, married (vs single), later years of diagnosis, certain SEER regions, and earlier stage. In the propensity-score matched cohort, brachytherapy treatment was associated with lower 4-year cumulative incidence of cancer death (32.1% vs 43.4%; P < .001) and better overall survival (64.0% vs 51.4%; P < .001). Brachytherapy treatment was independently associated with lower CSM (hazard ratio, 0.70; 95% CI, 0.64-0.76; P < .001) and ACM (hazard ratio, 0.72; 95% CI, 0.67-0.78; P < .001). CONCLUSIONS: Brachytherapy utilization among SEER regions has improved since 2004 in patients with stage IB2-IVA cervical cancer. Brachytherapy use remains independently associated with significantly lower CSM and ACM and is an essential component of treatment for patients with locally advanced cervical cancer.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Han K, Colson-Fearon D, Liu ZA, et al. Updated Trends in the Utilization of Brachytherapy in Cervical Cancer in the United States: A Surveillance, Epidemiology, and End-Results Study. Int J Radiat Oncol Biol Phys. 2023. PMID: 37951548. doi:10.1016/j.ijrobp.2023.11.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。